$GILD Company News Lobbyists for insurers, big pharma

New Post Public Reply Private Reply Replies (0) Message Board

Jun 3, 2014 at 10:37 AM

$GILD Company News

Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com

Applied Genetic (AGTC) Soars: Stock Up 44.1% - Tale of the Tape 58 min ago - Zacks.com
Gilead CLL drug effective in Phase 2 trial 9:30 a.m. Today - Seeking Alpha
Puma Biotechnology (PBYI) Crumbles: Stock Plunges by 25.3% - Tale of the Tape 8:45 a.m. Today - Zacks.com
Ariad Pharmaceuticals (ARIA) Catches Eye: Stock Up 7.43% - Tale of the Tape 8:44 a.m. Today - Zacks.com
UPDATE: Gilead Reports Updated Phase 2 Results for Investigational GS-9973, Showed 49% Overall Response Rate with Est. Progression-Free Survival Rate at 24 Weeks 70% 7:33 a.m. Today - benzinga.com
Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C 5:59 a.m. Today - CNW Group
Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C 9:20 p.m. June 2, 2014 - CNW Group
Patent infringement suit dismissed 6:30 p.m. June 2, 2014 - Seeking Alpha
Roche Acquires Genia Technologies - Analyst Blog 4:40 p.m. June 2, 2014 - Zacks.com
Merck Presents Positive Trial Results For Cancer Drug 4:12 p.m. June 2, 2014 - Investors Business Daily
Myriad Genetics to Unveil BRACAnalysis, HRD Data - Analyst Blog 3:30 p.m. June 2, 2014 - Zacks.com
Why Vertex Pharmaceuticals Will Likely Climb to New High 1:26 p.m. June 2, 2014 - TheStreet.com
Value Of U.S. Equity Buybacks In May Drops 12:53 p.m. June 2, 2014 - benzinga.com
Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog 12:10 p.m. June 2, 2014 - Zacks.com
NPS Pharma on Shire's Radar? - Analyst Blog 11:30 a.m. June 2, 2014 - Zacks.com
Stock Market News for June 02, 2014 - Market News 10:06 a.m. June 2, 2014 - Zacks.com
Retrophin (RTRX) Jumps: Stock Adds 13.5% in Session - Tale of the Tape 9:25 a.m. June 2, 2014 - Zacks.com
Allergan Inc. (AGN) in Focus: Stock Rises 5.65% - Tale of the Tape 8:44 a.m. June 2, 2014 - Zacks.com
Analyst Cancer and Biotech Stock Picks From ASCO 7:57 a.m. June 2, 2014 - 247WallSt.com
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients 7:35 a.m. May 31, 2014 - TheStreet.com

Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. Today - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma 12:37 p.m. May 6, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases July Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:15 p.m. May 2, 2014 - PR Newswire - PRF
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors 9:00 a.m. April 30, 2014 - PR Newswire - PRF
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver 9:31 a.m. April 29, 2014 - PR Newswire - PRF
Federal Circuit Rules for Axinn Client Natco Pharma Ltd. in Tamiflu Patent Appeal 1:50 p.m. April 25, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

xTool X1: Redefining Laser Fabrication for Makers

The Next Generation of Laser Fabrication Whenever a new gizmo hits the market, it's usually just an upgrade in disguise—faster, shinier, a touch more wattage. Not this time. xTool shook things up by rolling out the X1, a laser platform that gets what small businesses and makers truly crave: versatility and long-lasting potential. This bad boy does more than engrave; it...

Broadway.com Instagram Reaches Million Followers Milestone

Broadway.com's Instagram Ascends to Iconic Status There it is, folks—Broadway.com's Instagram just threw down the gauntlet with a clean, million-follower milestone. That's right, a hefty chunk of people now have a front-row seat to Broadway's electric world, straight from their phones. If you're a Broadway buff or just a casual admirer of glitz and glam, these numbers...

Chicago's Public Safety Gets Asset Management Overhaul

SDI Presence Gives Chicago's Public Safety a Tech Boost When it comes to keeping a city as bustling as Chicago in check, the right tools can make all the difference. Enter SDI Presence, who just gave the city's Public Safety Administration (PSA) a digital makeover through a new Enterprise Asset Management solution on the ServiceNow platform. Streamlining and Centralizing...

ODNB and NACB Merge: A Big Leap in Community Banking

Merging Titans in Community Banking Folks, we've got a colossal merger happening in the cozy yet combative world of community banking—ODNB Financial Corporation is hitching wagons with National Capital Bancorp, Inc. Now, you'd be forgiven for not popping champagne over this unless your bread is buttered by $2.4 billion in assets and the shiny allure of becoming a big...

Xerox Faces Probes After $130M Profit Forecast Slash

When the Trust Breaks October 29, 2026 was a gut punch for Xerox investors. Watching the outlook dive by $130 million, the coffee-feeling in the trading rooms turned into something more bitter. A $105 million boost they once celebrated from tariff receivables now seems to be a fleeting shadow, as Xerox itself scuttles its adjusted operating income for 2026 to a range of...

Keith Strachan Elevates The Master Group's Strategy

Strachan Steps Up as Chief Commercial Officer Keith Strachan is stepping into the role of Chief Commercial Officer at The Master Group—big news up in St-Bruno-de-Montarville. Now, those not neck-deep in HVAC-R might shrug this one off, but for those eyeing the industry, this is where the cards start to shuffle in North America. Master’s shift isn't just paper-pushing;...

Vuzix to Reveal Q3 2026 Results in Upcoming Call

Vuzix Sets the Stage for Its Q3 2026 Earnings Call Out of all the snazzy tech plays you scribble down on a placemat over morning coffee, Vuzix Corporation (NASDAQ: VUZI) is gearing up for some spotlight action. This November 12, at 4:30 PM Eastern Time, they’re unveiling their third quarter 2026 earnings results, piping hot through a conference call. It's the kind of...

Sweco: Europe’s Water Resilience Faces Tough Challenges

Tackling Europe's Water Resilience Ah, water infrastructure—it's that unglamorous pillar we often overlook until nature reminds us of its importance, sometimes with a swift, wet slap across the face. Sweco's recent report might not grab flashy headlines, but it's a good reminder for Europe that smarter investments in water resilience ain't just good advice; it's a damn...

KLX Energy Refreshes Board with Seasoned Directors

A New Chapter for KLX Energy Services KLX Energy Services has just reshuffled its board, and it's stirring interest. With Franklin S. Edmonds, Jr. and E. Dirk Hallen stepping into the roles of independent directors, effective October 29, 2026, there's change in the air. They take over from John Collins and Tom McCaffrey, who've been holding the fort during some...

FirstEnergy Bolsters Support for Shelter Initiatives

FirstEnergy Foundation's Commitment Shines Bright Alright, here's the scoop. FirstEnergy Foundation isn't just about keeping the lights on anymore. They're throwing down $620,000 to tackle one hell of a tough nut—shelter and stability. This latest infusion spreads across five states, with ten nonprofit warriors in New Jersey alone locking in $120,000 of that pot for...